Insilico Medicine Secures $110 Million Series E Financing to Accelerate AI- and Robotics-Driven Drug Discovery Innovation

Dr. Liang Chuanxin, Partner (Healthcare Investment) at Value Partners Groupstated, “We are honored to partner with InSilico Medicine as co-investors, joining forces to revolutionize the drug discovery and development process through artificial intelligence and automation technologies. InSilico Medicine holds a leading position in AI-driven drug development, with proven track records, placing the company at the forefront of industry transformation. We believe that InSilico Medicine will not only accelerate the development of urgently needed clinical therapies for patients but also reshape the future of biopharmaceutical R&D. This collaboration also marks a significant milestone in Value Partners Group’s private equity investment strategy, reflecting our vision to invest in disruptive technologies with the potential to transform industries.”

Wen Xinchun, Secretary of the Party Committee and Executive Director of Pudong Venture Capital Group“[The representative] stated, ‘As a benchmark enterprise in the global AI-driven biopharmaceutical sector, InSilico Medicine exemplifies innovation and technological prowess. The co-leading of InSilico Medicine’s Series E financing round by Shanghai Pudong Venture Investment Co., Ltd. represents another significant practice of our strategy to focus on six core hard-tech industries, strengthen and secure industrial chains, and prioritize investing in innovative and high-quality ventures. Committed to fostering technological innovation and promoting the development of emerging industries, Shanghai Pudong Venture Investment looks forward to InSilico Medicine injecting stronger innovative momentum into the biopharmaceutical industry through its global perspective and leading-edge technologies. Moving forward, we will continue to leverage capital as a link to support more sci-tech enterprises with breakthrough potential, accelerate the commercialization of scientific research achievements, and advance the development of innovation hubs, thereby empowering the technological innovation ecosystem in Pudong New Area and globally.’”

Li Junlan, Party Secretary and Chairman of Pudong Development Group“He stated, ‘InSilico Medicine is the first innovative sci-tech startup invested in by the SPDB Group’s Park Fund, fully demonstrating the strategic positioning of SPDB’s Sci-Tech Innovation Parks in cultivating high-growth enterprises and serving technological innovation. This collaboration with InSilico Medicine is not merely an investment partnership but also a cooperation within the industrial ecosystem. SPDB Group will leverage the synergistic effects of its “fund + base + industrial platform” model to support the company’s development throughout its entire lifecycle, empowering InSilico Medicine to establish its China regional sci-tech innovation headquarters at the SPDB Upper Town project. We believe that the driving force exerted by leading enterprises on their upstream and downstream industries is irreplaceable. We look forward to attracting high-quality projects represented by InSilico Medicine, thereby providing sustained momentum for building a high-quality innovation ecosystem and perfecting an industrial chain system with global influence.’”

Dr. Alex Zhavoronkov, Founder and CEO of InSilico Medicinestated, “We are delighted to have secured $110 million in Series E financing. I believe this is a significant milestone that not only reflects our unwavering commitment to transforming healthcare but also demonstrates investors’ strong confidence in us. Led by Value Partners Group and driven by industry-focused investors, this round was heavily oversubscribed and attracted interest from numerous renowned investors. The proceeds from this round will accelerate the development of our drug pipeline and artificial intelligence platform, further solidifying InSilico Medicine’s leadership position in this rapidly evolving field. We remain dedicated to our mission of extending high-quality healthy human lives and take pride in standing at the forefront of healthcare innovation.”

Since the last round of financing, InSilico Medicine has made significant progress in the development of its artificial intelligence platform and the expansion of its drug discovery pipeline. Real-world case studies have validated the capability of its proprietary AI-driven platform to substantially reduce costs and enhance efficiency during the early stages of drug discovery. As demonstrated by publicly disclosed key benchmarks for its proprietary preclinical candidate (PCC) compounds, InSilico Medicine has reduced the average time required to nominate a PCC to 12–18 months by integrating advanced artificial intelligence and automation technologies, compared to the 2.5–4 years typically required by traditional drug discovery methods. Furthermore, each project requires the synthesis and testing of only 60 to 200 molecules.

Pharma.AI is a proprietary platform developed by InSilico Medicine, which maintains its technological leadership through two major updates annually. Centered on generative artificial intelligence and continuously integrating cutting-edge technologies, the Pharma.AI platform provides comprehensive solutions spanning biology, generative chemistry, clinical medicine, and scientific research. With ongoing technological advancements, InSilico Medicine has further enhanced the Pharma.AI platform by launching new engines based on large language models (LLMs), including Nach01, a multimodal foundation model for natural and chemical languages, and Dora, an agent-driven generative research assistant. Recently, InSilico Medicine also deployed the first humanoid robot scientist in Life Star1, its automated laboratory connected to Pharma.AI, to further optimize automated research workflows.

To date, driven by the Pharma.AI platform, InSilico Medicine has rapidly established a pipeline of more than 30 drug development programs, 10 of which have received approval to initiate clinical trials. Among these projects, the most advanced candidate, Rentosertib (ISM001-055), for the treatment of idiopathic pulmonary fibrosis (IPF), has progressed through multiple clinical studies and achieved encouraging results. In a recently completed Phase IIa clinical trial, Rentosertib demonstrated favorable safety and tolerability across all dose levels, while subjects exhibited dose-dependent improvements in forced vital capacity (FVC) after 12 weeks of continuous dosing.

Furthermore, by centering its business model on out-licensing transactions of its pipeline assets, InSilico Medicine has established sustainable revenue streams. The company has entered into four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, with a total value exceeding $1.5 billion. Meanwhile, InSilico Medicine has engaged in multiple drug R&D collaborations with industry partners such as Sanofi, Saudi Aramco, and Therasid Bioscience. Several of these collaborative projects have achieved milestone progress, resulting in milestone payments to InSilico Medicine and further driving the company’s financial growth.

With the successful completion of this round of financing, InSilico Medicine will continue to efficiently advance AI-driven biopharmaceutical R&D, comprehensively deepen collaboration across the industrial value chain, and explore the application of its AI platform in diverse scenarios within the life sciences sector through benchmark case studies.

InSilico Medicine is a clinical-stage biotechnology company powered by generative artificial intelligence. By integrating biology, chemistry, clinical medicine, and scientific research through next-generation AI systems, and leveraging modern machine learning techniques such as deep generative models, reinforcement learning, and transformer models, the company has built a robust and efficient AI-driven drug discovery platform. This platform enables the identification of novel targets and the generation of candidate drugs with specific molecular structures. InSilico Medicine focuses on areas of unmet medical needs, including cancer, fibrosis, immunology, central nervous system disorders, and age-related diseases, to advance and accelerate the development of innovative therapeutics.

Value Partners is a leading independent asset management company in Asia, dedicated to providing world-class investment services and products. Since its establishment in 1993, Value Partners has consistently adhered to a value investment strategy in both Asian and global markets. In November 2007, Value Partners Group became the first asset management company to be listed on the Main Board of The Stock Exchange of Hong Kong (Stock Code: 806.HK). Headquartered in Hong Kong, Value Partners Group maintains offices in Shanghai, Shenzhen, Singapore, and London. Its investment strategies span equities, fixed income, multi-asset, alternative investments, real estate, and quantitative investments, serving institutional and individual investors across the Asia-Pacific region, Europe, and the United States.